TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06331143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Mid-Transverse Process to Pleura (MTP) Block
Description: Patients will receive MTP block after induction of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Patients will receive intrathecal morphine in a dose of 12 μg/kg (max 1000 μg) immediately after induction of anesthesia.
Study: NCT05481086

Intervention type: OTHER
Intervention: No Interventions
Description: There is no interventions in this study
Study: NCT06073301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)
Description: Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)
Description: Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
Study: NCT05836896

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
Description: Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
Study: NCT06410196

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mood modulation
Description: Autobiographical memory recall designed to modulate mood and affective state by reminiscing about personal life events

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood modulation
Description: Autobiographical memory recall designed to modulate mood and affective state by reminiscing about personal life events
Study: NCT05576454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab Injection (BAT2606 Injection)
Description: In this group, each subject will receive single subcutaneous injection of 100 mg BAT2606 Injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab Injection (EU-licensed Nucala)
Description: In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab Injection (US-licensed Nucala)
Description: In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
Study: NCT06116370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rezum procedure
Description: In Rezūm procedure, the Rezūm System (NxThera Inc., Maple Grove, MN, USA) consists of a radiofrequency (RF) power supply generator and single-use transurethral delivery device. Starting 1 cm distal to the bladder neck, injection was done at 3 and 9 o'clock sites. The needle was inserted for 9 s duration, retracted, and then delivered to another treatment site in 1 cm distance distal to the previous one.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-TURP procedure
Description: In B-TURP, Olympus SurgMaster™ UES-40 bipolar generator (Olympus Europe, Hamburg, Germany) was used. Current's settings used were cut/coag 200/120. Using continuous flow 26Fr resectoscope first resection of the median lobe from the level of the bladder neck to the apex of the prostate was done followed by resection of the lateral lobes. Using Ellic evacuator, Prostatic chips were extracted from the field. A 22 fr three-way silicon Foley catheter was placed with traction applied and the balloon inflated by normal saline of 30-80 cc according to the size of the prostate.
Study: NCT05021861

Intervention type: DRUG
Intervention: Cyproterone Acetate, Ethinyl Estradiol Drug Combination
Description: FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS

Intervention type: DIAGNOSTIC_TEST
Intervention: FEMALE PATIENTS WITH PCOS
Description: FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,

Intervention type: DIAGNOSTIC_TEST
Intervention: Control group
Description: SYSTEMICALLY HEALTHY FEMALES
Study: NCT06347120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube
Description: nasogastric tube (NGT), intravenous administration of fluids, and clinical and biochemical monitoring for 72h.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NOM without NGT insertion
Description: intravenous administration of fluids, nill per os, analgesic, antiemetic treatment, and clinical and biochemical monitoring for 72h
Study: NCT05779189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-based virtual reality (Game)
Description: Besides reading the health education flier, they also need to trained with the game-based virtual reality in Biodex Medical Systems, which is a machine, includes 4 games: Catch Game, boating, Ball Maze, and Word Search. And all of the games are balance control games. The games were implemented in person for 30 minutes one time, total is 16 times (once to twice day a week).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional health education
Description: The health education flier was made refer to medical institutions, e.g., hospitals or clinics, the video of balance exercise was collected from the internet. Participants were assigned to read the health education flier, and follow suit the video of balance exercise at home of their free will.
Study: NCT05702606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Description: Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Description: Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT)
Description: Radial shock waves are ballistic waves generated by injection of compressed air inside an applicator that fires a projectile into the itself and impacts against the application head
Study: NCT06117319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual assistance Virtual reality training sessions
Description: 5 virtual reality training sessions where feedback will be provided to each individual by the research team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collective assistance Virtual reality training sessions
Description: 4 virtual reality training sessions where feedback will be provided to the whole group by the research team and 1 session where feedback will be individual.
Study: NCT06516536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBI (Mindfulness-Based Intervention)
Description: Breath-Focused Meditation Approach (5-7 minutes):~They will be guided to observe the flow of air in and out of the nose, noting sensations in the abdomen or chest.~Body scan (7-8 minutes):~Students will be guided through a careful exploration of their body. You'll start with your toes and slowly work your way toward your head, paying attention to the physical sensations in each part of your body.~Simple yoga poses (5-7 minutes):~Students will stand and follow instructions to perform a series of simple poses, such as mountain pose, tree pose, and cat-cow pose.
Study: NCT05716282

Intervention type: OTHER
Intervention: Accuracy of neuromuscular recovery estimation
Description: Accuracy of the estimation of neuromuscular recovery will be measured as:~* Correct attribution of the patients to the groups slow, intermediate or fast recovery~* Real speed of recovery falls between 95 confidence interval of the estimated speed of recovery
Study: NCT05601895

Intervention type: DRUG
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study: NCT05069493

Intervention type: PROCEDURE
Intervention: simple suturing
Description: Hiatal hernia repair by simple suturing of the diaphragmatic

Intervention type: PROCEDURE
Intervention: mesh
Description: Hiatal hernia repair by tension-free mesh closure
Study: NCT06139367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3454 tablets
Description: TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3454 tablets
Description: TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.
Study: NCT04836780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone base 6 mg once daily for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone base 6 mg once daily for seven days
Study: NCT04674761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odevixibat
Description: Odevixibat is a small molecule and selective inhibitor of IBAT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to experimental drug (odevixibat).
Study: NCT05803733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with low load resistance training
Description: Combination of low load resistance exercise in the upper limb.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine strength training
Description: range of motion exercises and strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine strength training
Description: range of motion exercises and strength training
Study: NCT04061330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
Study: NCT04921072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constant practice conditions
Description: CG will be practicing only one specific pattern of step isometric contractions (SPSIC) scheme. It means that 90 trials in all training sessions will consist only of SPSIC 1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable practice conditions
Description: VG will practice three SPSIC's (1-3). Each SPSIC will be practiced 30 times per session, which means that each session will consist of 90 SPSIC like CG.
Study: NCT05221957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron(III)isomaltoside
Description: Individual weight and hemoglobin dependent dosage
Study: NCT05812729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resiLIR Basic
Description: Each module contains psychoeducational elements as well as practical exercises.~Week 1: Introduction + Stress and resilience~Week 2: Optimism~Week 3: Mindfulness~Week 4: Sense of coherence and values~Week 5: Acceptance~Week 6: Self-compassion + Conclusion
Study: NCT04963868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent removed by the novel strategy
Description: The stent was removed during the last necrosectomy when the endpoint of necrosectomy was achieved；

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent removed by the conventional strategy
Description: The stent was removed after the last necrosectomy when clinical symptoms were relieved and fluid was nearly completely resolved confirmed by CT image.
Study: NCT05556811

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Light Therapy Device, LSA-1
Description: Dynamic Light Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Light Therapy Device, LSA-2
Description: Dynamic Light Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Light Therapy Device, LSA, 3
Description: Dynamic Light Therapy
Study: NCT06653179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral Erector Spinae Plane Block
Description: The patient is placed in the prone positionon a procedure table. The sacral region is exposed, and the area is prepped with antiseptic solution under sterile conditions. The ultrasound high-frequency linear transducer is placed transversely over the sacrum. The sacral cornua are typically seen as bony structures adjacent to the sacral hiatus, appearing as two hyperechoic structures. Rotate the ultrasound probe to a sagittal position over the sacrum to align with the fourth and fifth sacral vertebrae. Under continuous ultrasound guidance, block needle is inserted in-plane with the ultrasound probe. Direct the needle through the soft tissue towards the plane between the erector spinae muscle and the sacrum. After confirming needle placement, the injectate mixture of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is administered. A total volume of 10 mL is injected, and real-time ultrasound is used to observe the spread of the injectate within the target tissue plane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection
Description: The patient is positioned in the prone position on the procedure table, and the sacral region is exposed and prepped with antiseptic solution under sterile conditions. The fluoroscope is positioned laterally to visualize the sacral hiatus. Under fluoroscopic guidance, the block needle is inserted through the skin and advanced toward the sacral hiatus. Continuous fluoroscopy is used to ensure correct needle placement, typically visualized at the level of the sacral canal. After confirming the appropriate position with contrast media, the injectate consisting of 8 mg dexamethasone and 10 mg bupivacaine (0.5% concentration) is slowly administered, with a total volume of 10 mL. During injection, careful monitoring of the needle position is performed to avoid intravascular injection. After the procedure, patients are monitored for potential complications such as hypotension and allergic reactions.
Study: NCT06651866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-CMG
Description: Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.~* Level 1: 12mg/m2, IV drip, day 4;~* Level 2: 18mg/m2, IV drip, day 4; Decitabine: 25mg, IV drip, days 1-3; Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10; G-CSF: 300 ug, IV drip, days 1-5; Each cycle is 4 weeks, with a total of 2 cycles, and DLT is observed in the first cycle.~Note: Patients who achieve CR (Complete Remission) and PR (Partial Remission) in the first cycle can continue with the original dose for one more cycle, and then the investigator decides whether to continue this regimen or choose another regimen for maintenance therapy; Patients with NR (No Remission) in the first cycle will be withdrawn from this study.
Study: NCT05676177

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultra Low Dose CT
Description: * Two immediately consecutive scans with either one or two breath-holds~* First scan (ULD_DECT_1) 140 kilovolt peak (kVp) - fixed current 10 or 20 milliampere (mA) (if body mass index (BMI)\>30), that is 5 or 10 mAs~* Second scan (ULD_DECT_2) 80 kVp - fixed current 20 or 40 mA (if BMI\>30), that is 10 or 20 mAs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fat quantification MRI
Description: Dual echo scans, as well as proton density fat fraction (PDFF) scans, will be performed to assess liver fat fraction
Study: NCT05293223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCov
Description: Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months
Study: NCT06120374

Intervention type: RADIATION
Intervention: Radiotherapy
Description: For participants eligible for enrollment, radiotherapy was started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT) with daily image-guided radiotherapy (Daily IGRT) technique was used.~Range of irradiation (patients were randomized into two groups - expanded field irradiation group and involved field irradiation group)

Intervention type: DRUG
Intervention: Chemotherapy
Description: For patients eligible for enrollment, postoperative adjuvant chemotherapy was initiated at about 4-6 weeks after surgery, for a total of 4 cycles, with the chemotherapy regimen of gemcitabine + cisplatin. Administration: Gemcitabine 1,000 mg/m2 on days 1 and 8 (completed within 30-60 minutes), cisplatin 70 mg/m2 on day 1.

Intervention type: DRUG
Intervention: Immunotherapy
Description: For patients eligible for enrollment, sequential adjuvant immuotherapy was initiated at about 4-6 weeks after surgery, Immunotherapeutic agents include (PD-1/PD-L1) to be used every 21 days postoperatively for one year.
Study: NCT04818853

Intervention type: OTHER
Intervention: Observation to monitor patients for these infections
Description: We will be receiving discarded specimens weekly. From these we are going to identify these various potential infections.
Study: NCT05060029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Species
Description: Lactobacilli containing suppositories have been successfully used in the past to maintain the vaginal environment and for treatment of infections like BV. Some of the Lactobacilli species that have been used include Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus gasseri and Lactobacillus plantarum, none of which demonstrated any safety concerns. The investigational product, which contains a Lactobacilli complex as its main component, has already been marketed as a tool to maintain vaginal microbial balance, pH and the prevention of microbial infection, thus there are no additional safety concerns or risks involved in this clinical trial design.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coconut Oil Fatty Acids
Study: NCT06339372

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard feeding
Description: Patients received only standard feeding with caloric distribution (45%-50% carbohydrates,20_35% from fats and 10-35% from protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 and dipeptiven
Description: Patients received perioperative supplementation with omega 3 and dipeptiven (immunonutrition mixture) plus standard feeding.
Study: NCT06188143

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ibuprofen-Paracetamol
Description: Ibuprofen 40mg and Paracetamol 500mg per oral, single dose each, in study group 30minutes before hysteroscopic procedure
Study: NCT05727124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poul Gjessing
Description: maxillary canine retraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T loops
Description: T loops
Study: NCT04791163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Socket evaluation
Description: The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socket evaluation
Description: The subject will wear the socket for 4 weeks, and then reply questionnaires and achieve a 2-minute walking test
Study: NCT05430997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOB Warming Unit (WU505) + Inflatable Warming Blanket
Description: The inflatable warming method (Inflatable Warming Unit (IOB Warming Unit, WU505) + Inflatable Warming Blanket (IOB Warming Blanket)) is a common clinical warming technique in anesthesiology, which is well tolerated by patients and safe and effective. The anesthesiology department has established standard operating procedures for the above-mentioned non-invasive operations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cover with a quilt from the neck to both feet
Description: The patient was covered with a quilt from the neck to both feet after entering the operating room.
Study: NCT05659186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg PO QD

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Multimodal Radiotherapy
Study: NCT05647148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: In the first part of this audio material, which consists of three parts; The definition of deep relaxation, its purpose and points to be considered during exercise are included.~The second part, consisting of an average of thirty minutes, includes the explanation of relaxation exercises with verbal commands accompanied by the sound of the stream.~In the last part, there is only relaxation music without any commands.
Study: NCT04065672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Description: After a 4-week screening period, patients received IL-2 at a dose of 1 million IU subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.